Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAN-COVID pragmatic randomized trial of variant-containing Spikevax versus placebo in adults aged 50-64 years
2025-523841-82-00Phase 4Completed
- Sponsor
- Gentofte Hospital, Moderna Inc.
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing Spikevax variant-containing vaccine with Placebo (saline) (2 arms). Primary endpoint: Medically attended COVID-19. Started Dec 2025; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2025-523841-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523841-82-00.